Veeva Systems Shares Climb on Surging Volume Rank 418th as Institutional Activity and Strategic Cloud Updates Drive Optimism
Veeva Systems (VEEV) rose 0.72% on September 25, 2025, with a trading volume of $270 million, a 44.16% increase from the prior day, ranking 418th in volume across the stock market. The move followed a surge in institutional activity and strategic updates in its cloud solutions for life sciences clients, signaling renewed confidence in its long-term growth prospects.
Recent developments highlighted Veeva’s progress in expanding its healthcare data infrastructure, including a partnership with a major pharmaceutical firm to enhance drug development workflows. Analysts noted the agreement could solidify its market leadership in cloud-based R&D tools, differentiating it from competitors in a sector experiencing rapid digital transformation. Additionally, a regulatory filing revealed updated capital allocation plans, emphasizing investments in AI-driven analytics to improve client retention rates.
To run this back-test accurately, I’ll need a few extra details to define the strategy unambiguously: 1. Stock universe—Do you want all U.S.-listed common stocks (NYSE/NASDAQ/AMEX), only S&P 500 constituents, or another universe? 2. Position sizing—Should the 500 selected names each receive an equal dollar weight, or another weighting rule? 3. Execution prices—The usual approach is: Select the day’s top-500 names by total share volume at the close of day t. Enter positions at the close of day t (or the next day’s open) and exit at the close of day t+1. Please confirm whether that trade timing works for you. 4. Cash treatment & transaction costs—Any assumptions on commissions, slippage, or financing costs? If none, I’ll assume zero. Once I have these points, I can set up the data retrieval plan and run the back-test.

Hunt down the stocks with explosive trading volume.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments
No comments yet